On September 8^th, GoBroad Healthcare Group and Qitan Tech announced the establishment of a strategic partnership. This collaboration will focus on addressing the precise diagnostic and therapeutic needs of patients with hematological disorders. By leveraging GoBroad Healthcare Group’s clinically-driven innovation platform and Qitan Tech’s global leadership in next-generation gene sequencing technology, the partnership aims to foster in-depth cooperation across multiple domains, including disease diagnosis and treatment, scientific research, the translation of research findings, talent development, and professional exchange. Together, they aspire to overcome the challenges in clinical diagnosis and treatment, driving the advancement of precision medicine in hematology and bringing new hope to more patients suffering from hematological disorders.

On-site at the Strategic Cooperation Signing Ceremony between GoBroad Healthcare Group and Qitan Tech

Mr. Xu Feng, Chief Financial Officer of GoBroad Healthcare Group, and Mr. Bai Jingwei, Co-founder and Chief Scientist of Qitan Tech, delivered speeches on behalf of their respective organizations. In the presence of clinical experts, diagnostic specialists, and industry colleagues, Ms. Zhou Xuan, Executive Director of Shanghai Zhaxin Hospital/Liquan Hospital, affiliated with GoBroad Healthcare Group, and Mr. Lin Jianxun, Vice President of Qitan Tech, formally signed the strategic cooperation agreement on behalf of their respective parties.

Ms. Zhou Xuan and Mr. Lin Jianxun

Mr. Xu Feng stated that GoBroad Healthcare Group is committed to developing an integrated platform for medical services and technological innovation, spanning across "medicine, production, and research." The Group continues to focus deeply on specialized fields such as hematologic diseases and oncology, with the aim of leveraging its extensive clinical resources and research capabilities to optimize diagnosis and treatment practices driven by clinical needs and led by technological innovation. He expressed confidence that the strategic partnership with Qitan Tech will enable both organizations to fully capitalize on their strengths in the healthcare sector. This collaboration is expected to actively promote the clinical adoption and widespread application of next-generation sequencing technologies, particularly nanopore sequencing. By empowering various stages of clinical practice and research in hematology, the partnership aims to better address the diverse health needs of hematologic patients.

Mr. Xu Feng

Mr. Bai Jingwei stated that Qitan Tech, as a pioneer in domestic nanopore sequencing technology, has successfully overcome critical technological “bottlenecks” in the life sciences sector, achieving independent control over next-generation gene sequencing technology. He expressed confidence that, with the strong support of GoBroad Healthcare Group's extensive clinical experience and outstanding talent pool, both parties will fully leverage the core strengths of nanopore sequencing technology - namely its capabilities in “length, speed, breadth, accuracy, and flexibility”. This collaboration will significantly enhance diagnostic precision and research efficiency, providing patients with hematological diseases more effective, accurate, and personalized clinical diagnosis, treatment, and health management services.

Mr. Bai Jingwei

Infections are a common clinical challenge faced by both hematological patients and hematologists. The accuracy of diagnosis and the timeliness of treatment are crucial factors that directly impact patient outcomes. However, traditional pathogen detection methods are increasingly inadequate for modern clinical needs due to their limited scope in identifying microbial species, long reporting times, and high sample requirements. The signing of this strategic partnership signifies a major step forward in the collaboration between the two parties in the field of personalized treatment and precision medicine for hematologic diseases. It lays a strong foundation for delivering higher-quality, more efficient precision diagnosis and treatment, as well as clinical research in hematology. Moving forward, the two organizations will focus on precision detection as a key entry point, strengthening the integration of industry, university, and research. This collaboration will accelerate the exploration of new paradigms in precision medicine, improve the quality of healthcare services, drive the development of the biopharmaceutical industry, and contribute to the realization of the Healthy China initiative.

About GoBroad Healthcare Group

GoBroad Healthcare Group (GHG) is committed to the principle of "the needs of the patient come first" and aims to quest for excellence in diagnosis treatment, explore technological innovation, and create the possibilities in life. The Group’s mission is to build a clinical-driven platform for innovative medical technologies. Founded in 2017, GHG focuses on clinical treatment, clinical research, reference laboratories and information technology. GHG currently operates seven hospitals in Beijing, Shanghai and Guangzhou, with a combined open bed capacity of nearly 1,500 beds. GHG specializes in innovative and research-active specialties such as solid tumors, hematologic diseases, and brain science. GHG has established professional service fields including a Phase I clinical trial ward, a central laboratory, an early-stage clinical research center, while providing clinical pharmacology, medicine and statistical analysis. With the medical mission of treating severe diseases that have proved to be difficult to treat, GHG has brought more treatment options and hope to the vast number of patients with severe diseases that are difficult to treat. With the scientific research mission of promoting medical innovation, GHG has served hundreds of innovative pharmaceutical companies in a large number of innovative drug clinical trials. Advances in medicine are stemmed from idea that encourages innovation, and improvements in innovation are derived from the practice of embracing medicine.

About Qitan Tech

Qitan Tech, with the mission of "making life's information readily accessible," is China’s first and the world’s second high-tech enterprise to independently develop and commercialize a nanopore gene sequencing platform. The company is dedicated to leading the new era of gene sequencing. Established in 2016, Qitan is recognized as a national "Specialized, Refined, Characteristic, and Innovative Small Giant Enterprise." In December 2021, Qitan has launched QNome-3841, which is the first commercialized nanopore sequencer in China, officially bridging the "last mile" of R&D transformation and initiating the era of localization of nanopore sequencing. Currently, Qitan has introduced two major nanopore sequencing platforms, QNome and QPursue, along with a range of comprehensive end-to-end product solutions. These innovations are widely applied across various sectors, including pathogen research, genetic disease diagnostics, oncology, animal epidemic prevention and control, forensic science, and public health surveillance. To date, Qitan has served over 200 institutional clients.